DDInter1055 DDInter1293
Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic [ofloxacin]. It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer). Levofloxacin, along with other quinolones such as [gatifloxacin] and [moxifloxacin], is a member of the third generation of fluoroquinolones, colloquially referred to as the "respiratory quinolones" due to improved activity against gram-positive bacteria commonly implicated in respiratory infections.[A31453,A190756] Levofloxacin was first approved by the FDA in 1996, and was approved in Canada and several South American countries soon after.
Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec), another tyrosine kinase inhibitor used as a first-line treatment for CML.
Levofloxacin {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Nilotinib
Levofloxacin {u} (Compound) downregulates {v} (Gene) ACD
ACD {u} (Gene) is downregulated by {v} (Compound) Nilotinib
Levofloxacin {u} (Compound) binds {v} (Gene) TOP2A
TOP2A {u} (Gene) is downregulated by {v} (Compound) Nilotinib
Levofloxacin {u} (Compound) causes {v} (Side Effect) Lymphopenia
Lymphopenia {u} (Side Effect) is caused by {v} (Compound) Nilotinib
Levofloxacin {u} (Compound) resembles {v} (Compound) Gemifloxacin
Gemifloxacin {u} may lead to a major life threatening interaction when taken with {v} Nilotinib
Levofloxacin {u} (Compound) resembles {v} (Compound) Sparfloxacin
Sparfloxacin {u} may lead to a major life threatening interaction when taken with {v} Nilotinib
Levofloxacin {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Ponatinib
Ponatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nilotinib
Levofloxacin {u} (Compound) downregulates {v} (Gene) ACD
ACD {u} (Gene) is regulated by {v} (Gene) HERPUD1
HERPUD1 {u} (Gene) is upregulated by {v} (Compound) Nilotinib
Levofloxacin {u} (Compound) binds {v} (Gene) TOP2A
TOP2A {u} (Gene) is associated with {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Nilotinib
Levofloxacin {u} (Compound) causes {v} (Side Effect) Lymphopenia
Lymphopenia {u} (Side Effect) is caused by {v} (Compound) Ponatinib
Ponatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nilotinib
Levofloxacin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Nilotinib (Compound)
Levofloxacin (Compound) downregulates ACD (Gene) and ACD (Gene) is downregulated by Nilotinib (Compound)
Levofloxacin (Compound) binds TOP2A (Gene) and TOP2A (Gene) is downregulated by Nilotinib (Compound)
Levofloxacin (Compound) causes Lymphopenia (Side Effect) and Lymphopenia (Side Effect) is caused by Nilotinib (Compound)
Levofloxacin (Compound) resembles Gemifloxacin (Compound) and Gemifloxacin may lead to a major life threatening interaction when taken with Nilotinib
Levofloxacin (Compound) resembles Sparfloxacin (Compound) and Sparfloxacin may lead to a major life threatening interaction when taken with Nilotinib
Levofloxacin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Ponatinib (Compound) and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Levofloxacin (Compound) downregulates ACD (Gene) and ACD (Gene) is regulated by HERPUD1 (Gene) and HERPUD1 (Gene) is upregulated by Nilotinib (Compound)
Levofloxacin (Compound) binds TOP2A (Gene) and TOP2A (Gene) is associated with hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Nilotinib (Compound)
Levofloxacin (Compound) causes Lymphopenia (Side Effect) and Lymphopenia (Side Effect) is caused by Ponatinib (Compound) and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib